CASI Pharmaceuticals, Inc.(CASI)

Description: CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

---

Keywords: Biotechnology Cancer Pharmaceutical Life Sciences Disease Solid Tumors Treatment Of Cancer Autoimmune Disease Platinum Cancer Treatment Leukemia Ovarian Cancer Multiple Myeloma Stage Pharmaceutical Advanced Solid Tumors Pyrrolidines Cyclacel Cell Cycle Pacritinib

---

Home Page: www.casipharmaceuticals.com

CASI Technical Analysis

9620 Medical Center Drive
Rockville, MD 20850
United States
Phone: 240 864 2600

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)